Opthea’s OPT-302 to be featured in oral presentation during ASRS 2023

Article

The oral presentation, entitled “Population Pharmacokinetics and Safety of OPT-302, an anti-VEGF-C/-D ‘trap’ in Patients with Retinal Vascular Diseases” will take place on 31 July, 2023 in Seattle, Washington.

An audience listens to a presentation at a conference. Image credit: ©kasto – stock.adobe.com

In addition, Opthea will also be featured in a wet age-related macular degeneration (wet AMD) virtual fireside chat. Image credit: ©kasto – stock.adobe.com

Opthea Limited has announced that OPT-302, the Company’s VEGF-C/D “trap” inhibitor will be highlighted during an oral presentation at the American Society of Retina Specialists (ASRS) 2023 Annual Meeting in Seattle, Washington.

During the scientific sessions at the ASRS conference, Dante Pieramici, MD, Director of the California Retina Research Foundation, Partner at California Retina Consultants, will present new pharmacokinetics and pooled safety data on OPT-302 as follows:

Oral presentation Title: Population Pharmacokinetics and Safety of OPT-302, an anti-VEGF-C/-D ‘trap’ in Patients with Retinal Vascular Diseases
Session: Pharmacology Symposium
Date and time: July 31, 2023, 4:10-4:14 pm PST

In addition, Opthea will also be featured in a wet age-related macular degeneration (wet AMD) Key Opinion Leader (KOL) virtual fireside chat discussing market trends and new treatments in wet AMD entitled “Live From ASRS” hosted by Hartaj Singh, Managing Director and Senior Biotechnology Analyst at Oppenheimer & Co. Two world renowned retina disease experts, Charles Wycoff MD, PhD, the Director of Research at Retina Consultants of Texas, Chairman of Research, Retina Consultants of America, and Deputy Chair of Ophthalmology for the Blanton Eye Institute, Houston Methodist Hospital, and Dante Pieramici, MD, will serve as panelists alongside Megan Baldwin, PhD, Opthea’s Chief Executive Officer.

The Oppenheimer & Co sponsored “Live from ASRS” wet AMD forum takes place on August 1, 2023 at 8 am PST. The session will be accessible virtually. Register at https://opco.zoom.us/webinar/register/WN_9HTx70FDRa6yIeUcEODn6w

Baldwin commented on the news in a press release, saying, “At a time when most new wet AMD treatment candidates are largely focused on extending dosing treatment intervals in wet AMD, we look forward to sharing new data on the pharmacokinetics of OPT-302 to improve upon vision outcomes for patients above what is currently achieved with standard-of-care anti-VEGF-A monotherapy. Opthea is also appreciative of Oppenheimer for featuring the current global Phase 3 clinical program of OPT-302 and its potential value as a novel wet AMD treatment, as part of the hosted 'Live from ASRS' KOL forum.”

Reference:

1. Opthea to Feature at the American Society of Retina Specialists 2023 Annual Meeting. Opthea Limited. July 13, 2023. Accessed July 17, 2023. https://www.globenewswire.com/news-release/2023/07/13/2704150/0/en/Opthea-to-Feature-at-the-American-Society-of-Retina-Specialists-2023-Annual-Meeting.html

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
© 2025 MJH Life Sciences

All rights reserved.